Revvity, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RVTY research report →
Range $115 – $200
Price Chart
About the company
Revvity, Inc. , founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc.
- CEO
- Prahlad R. Singh
- IPO
- 1965
- Employees
- 11,000
- HQ
- Waltham, MA, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a constructive multi-month uptrend, trading well above its 200-day average of 114.03 and its 50-day average of 150.40. It is still below the 52-week high of 171.74, so the setup is strong but not stretched into new-high territory.
Street sentiment is constructive: consensus sits at Buy with 15 buys and 15 holds, and the average target of 146.43 has been nudged higher by recent upgrades and target raises. The latest notes were mostly reiterations or fresh positive coverage, with BofA lifting its target to 185 and Barclays, KeyBanc, and others also moving higher.
Execution has been consistent, with Revvity beating EPS estimates in all 8 of the last 8 quarters. Next-year EPS is modeled at 5.96 versus a 2.25 TTM run rate, so shareholders should watch whether margin and revenue gains keep translating into faster earnings power.
Recent insider flow leans negative on discretionary activity, with 4 sales and no open-market buys. The selling came from officers, while the awards, gifts, and in-kind items are non-discretionary noise rather than a conviction signal.
Profitability is solid but not elite, with gross margin at 55.9% and operating margin at 16.7%. Growth is steady rather than explosive, with revenue up 4.3% year over year and earnings up 37.8%, supported by strong free cash flow of $655.3 million.
Revvity sits in the higher-quality end of life sciences tools and diagnostics, with recurring exposure across instruments, reagents, and software. Versus the sector, the valuation is not cheap at 28.86x earnings, but the premium is backed by consistent beats and improving earnings expectations.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $16.21B
- P/E
- 64.26
- Fwd P/E
- 26.77
- PEG
- 4.74
- P/S
- 5.51
- P/B
- 2.23
- EV/EBITDA
- 23.33
- Div Yield
- 0.19%
- Gross Margin
- 53.07%
- Op Margin
- 12.65%
- Net Margin
- 8.61%
- ROE
- 3.50%
- ROIC
- 3.11%
Latest fiscal year · YoY change
- Revenue
- $2.86B+3.7%
- Gross Profit
- $1.52B+14.6%
- Op Income
- $356.63M
- Net Income
- $241.68M-18.3%
- EPS
- $2.08-13.7%
- OCF Growth
- -7.4%
- FCF Growth
- -6.2%
- 52W High
- $171.74
- 52W Low
- $81.22
- 50D MA
- $152.79
- 200D MA
- $115.16
- Beta
- 1.09
- RSI (14)
- 41
- Avg Volume
- 1.91M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Revvity delivered a strong Q3 with 7% organic growth, margin expansion, and raised full-year guidance on broad-based strength in life sciences, diagnostics, and AI-related demand.· November 3, 2026
- Q3 pro forma organic growth was 7%, ahead of expectations, with revenue of $710 million and pro forma adjusted EPS of $1.37.
- Life sciences was the main driver, growing 9% organically, while diagnostics grew 5% organically and remained steady.
- Management said AI-related demand is expanding beyond high-content screening into more of the portfolio, including reagents, high-throughput screening, detection, and eventually imaging/in vivo.
- The company raised full-year pro forma organic growth guidance to about 5% and full-year pro forma adjusted EPS to $5.40-$5.45.
- Margins improved meaningfully: Q3 pro forma adjusted operating margin was 29.4%, and full-year margin guidance was raised to 28.8%.
Revvity reported Q3 total revenue of $710 million, with 7% organic growth. Life sciences revenue was $380 million, up 11% reported and 9% organic; diagnostics revenue was $330 million, up 4% reported and 5% organic. Pro forma adjusted operating margin was 29.4%, adjusted net interest and other expenses were $21 million, the adjusted tax rate was 18%, and adjusted EPS was $1.37, up 21% year over year. Free cash flow was $152 million in the quarter, with year-to-date free cash flow above $450 million and 105% conversion of adjusted net income. For full year 2026, management now expects pro forma organic growth of about 5%, pro forma revenue of approximately $2.86 billion, pro forma adjusted operating margin of 28.8%, net interest expense of about $88 million, and adjusted EPS of $5.40-$5.45. For Q4, guidance implies about $755 million of revenue at the midpoint, pro forma adjusted operating margin slightly above 32%, and pro forma adjusted EPS of $1.60 at the midpoint.
Prahlad R. Singh struck an upbeat tone, saying the quarter showed Revvity’s ‘true potential’ and that performance was driven by both a recovery in pharma/biotech demand and early AI-related tailwinds. He emphasized that AI is only in the ‘early days,’ but is already broadening demand across reagents, instruments, and software, and he pointed to new launches like Signals Logistics and the CE IVDR-certified GSP T1D 3-Plex kit as examples of innovation. He also highlighted operational improvements, especially in diagnostics and across the company’s footprint, and said the business is positioned for a strong finish to 2026 and better into 2027.
Maxwell Krakowiak focused on the financial execution: stronger revenue, favorable mix, and efficiency actions drove the quarter’s margin expansion and earnings upside. He cited Q3 revenue of $710 million, organic growth of 7%, pro forma adjusted operating margin of 29.4%, adjusted EPS of $1.37, and free cash flow of $152 million, with 99% conversion in the quarter and 105% year-to-date. He also noted balance-sheet improvement after retiring a €500 million note, ending the quarter at 2.3x net debt to adjusted EBITDA, while still targeting gross leverage below 3.0x and net leverage near 2.0x by year-end. On guidance, he raised full-year organic growth, margin, and EPS outlooks, and said most of the margin improvement is structural and should carry into next year.
Analysts pressed management on what was behind the strength in reagents and instruments, and whether the Q4 guide implied a step-down from Q3. Management said reagents benefited from both stronger underlying demand and some timing of screening orders, with about a 100-basis-point contribution from the bulk orders, while Q4 growth should moderate to the mid-single digits. On instruments, management said growth was broad-based rather than just HCS, backlog continued to build across most instrument groups, and capacity is being expanded. Several questions centered on AI exposure and whether demand is sustainable; management said AI is beginning to affect a wider set of products, but it is still early, and the broader recovery in pharma/biotech spending and capex is also supporting the business.
The bull case from this call is that Revvity is benefiting from both a cyclical recovery and a new AI-driven demand layer, with evidence now showing up across multiple parts of the portfolio rather than just one niche. Management believes the company’s operational changes are structural, supporting higher margins and stronger cash flow, while new product launches and backlog growth suggest momentum could continue into 2027.
The main risks discussed were that some Q3 strength was helped by timing, especially in reagents, and Q4 growth is expected to moderate from the Q3 pace. Management also repeatedly said the AI opportunity is still in early days, and diagnostics still faces China-related pressure, including a divestiture-related headwind and weak birth rates affecting reproductive health demand.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.5%
- Shares Outstanding
- 111.64M
- Float Shares
- 111.07M
of shares held by institutions
557 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for RVTY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Sell | Oct 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 13, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Sep 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Sep 4, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Sep 9, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | May 4, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | May 1, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Sep 12, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 26, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Aug 13, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 26, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jul 23, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jul 22, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Price T Rowe Associates Inc | 13.20M | ▲ 7.67M |
| Vanguard Group Inc | 13.16M | ▼ 357.16K |
| Jupiter Topco LLC | 8.64M | ▲ 8.64M |
| T. Rowe Price Investment Management, Inc. | 8.63M | ▼ 9.63M |
| Blackrock, Inc. | 7.78M | ▲ 120.40K |
| Janus Henderson Group Ltd. | 7.39M | ▲ 7.39M |
| Vanguard Capital Management LLC | 7.32M | ▲ 18.99K |
| Edgepoint Investment Group Inc. | 5.33M | ▼ 3.22M |
| Vanguard Portfolio Management LLC | 4.74M | ▼ 28.02K |
| State Street Corp | 4.37M | ▲ 28.16K |
| Dimensional Fund Advisors LP | 3.41M | ▼ 15.19K |
| Fmr LLC | 3.05M | ▲ 2.58M |
Held by 953 ETFs
Biggest fund positions in RVTY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Gonzales Anita | sell | 84 |
| Sep 21, 26 | Krakowiak Maxwell | sell | 1,631 |
| Sep 16, 26 | Vohra Tajinder S | sell | 7,330 |
| Aug 25, 26 | MICHAS ALEXIS P | other | 285 |
| Aug 14, 26 | Goldberg Joel S | other | 27,785 |
| Aug 14, 26 | Goldberg Joel S | other | 27,785 |
| Aug 13, 26 | Singh Prahlad R. | other | 7,636 |
| Aug 13, 26 | Singh Prahlad R. | other | 59,650 |
| Aug 13, 26 | Singh Prahlad R. | other | 7,636 |
| Aug 13, 26 | Singh Prahlad R. | other | 59,650 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RVTY coverage
Recent articles, reports, and earnings notes.

Revvity (RVTY): Recovery Story Meets Rich Valuation
Revvity is showing a real earnings recovery, led by strong Diagnostics growth and improving Life Sciences momentum. But the stock already reflects much of that progress, with leverage and valuation keeping the rating at Hold.

Revvity, Inc. (RVTY) rises 9% on beat-and-raise outlook
Revvity, Inc. (RVTY) rises sharply after conference commentary reinforced its better-than-expected second quarter and raised 2026 outlook. Strong volume, improving diagnostics momentum, and a breakout above its 52-week high are fueling the move, though valuation remains elevated and the stock now trades above the analyst consensus target.

Life Sciences Tools Stocks to Own in 2026: 7 Names to Know
A seven-stock countdown spans genomics, proteomics, diagnostics, analytical tools, bioprocessing, and broad laboratory platforms.
Want a deeper read on RVTY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Revvity Inc. $RVTY Position Trimmed by Bessemer Group Inc.
defenseworld.net · Nov 20
Diamond Hill Mid Cap Strategy Q3 2026 Portfolio Review
seekingalpha.com · Nov 18
Revvity, Inc. (RVTY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
Revvity to Showcase Strategy for Powering Scientific Intelligence at 2026 Investor Day
businesswire.com · Nov 13
NVIDIA (NASDAQ:NVDA) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.
defenseworld.net · Nov 13
ELV or RVTY: Which Is the Better Value Stock Right Now?
zacks.com · Nov 11
All You Need to Know About Revvity (RVTY) Rating Upgrade to Buy
zacks.com · Nov 6
Madison Mid Cap Fund Q3 2026 Portfolio Activity
seekingalpha.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 16, 2026 · Live quote · Not investment advice